In reply

Comment

Christopher M Wittich et al. Mayo Clin Proc. 2013 Mar.

. 2013 Mar;88(3):305-6.

doi: 10.1016/j.mayocp.2012.12.008. Epub 2013 Feb 27.

No abstract available

Comment on

Ten common questions (and their answers) about off-label drug use.
Wittich CM, Burkle CM, Lanier WL. Wittich CM, et al. Mayo Clin Proc. 2012 Oct;87(10):982-90. doi: 10.1016/j.mayocp.2012.04.017. Epub 2012 Aug 6. Mayo Clin Proc. 2012. PMID: 22877654 Free PMC article.
Off-label drug use: the bevacizumab story.
Stewart MW. Stewart MW. Mayo Clin Proc. 2013 Mar;88(3):305. doi: 10.1016/j.mayocp.2012.12.007. Epub 2013 Feb 27. Mayo Clin Proc. 2013. PMID: 23489456 No abstract available.

Off-label drug use: the bevacizumab story.
Stewart MW. Stewart MW. Mayo Clin Proc. 2013 Mar;88(3):305. doi: 10.1016/j.mayocp.2012.12.007. Epub 2013 Feb 27. Mayo Clin Proc. 2013. PMID: 23489456 No abstract available.
Ten common questions (and their answers) about off-label drug use.
Wittich CM, Burkle CM, Lanier WL. Wittich CM, et al. Mayo Clin Proc. 2012 Oct;87(10):982-90. doi: 10.1016/j.mayocp.2012.04.017. Epub 2012 Aug 6. Mayo Clin Proc. 2012. PMID: 22877654 Free PMC article.
Physicians' Perspectives on FDA Approval Standards and Off-label Drug Marketing.
Kesselheim AS, Woloshin S, Lu Z, Tessema FA, Ross KM, Schwartz LM. Kesselheim AS, et al. JAMA Intern Med. 2019 May 1;179(5):707-709. doi: 10.1001/jamainternmed.2018.8121. JAMA Intern Med. 2019. PMID: 30667474 Free PMC article.
Reducing off-label prescribing in psychiatry.
Hickie IB. Hickie IB. Med J Aust. 2014 Feb 3;200(2):65-6. doi: 10.5694/mja14.00050. Med J Aust. 2014. PMID: 24484086 No abstract available.
Racially and ethnically selective oligoanalgesia: is this racism?
Goldfrank LR, Knopp RK. Goldfrank LR, et al. Ann Emerg Med. 2000 Jan;35(1):79-82. doi: 10.1016/s0196-0644(00)70108-9. Ann Emerg Med. 2000. PMID: 10613944 Review. No abstract available.